Bayer Schering Pharma AG announces the kick-start of the TALENT study, a multicenter "STudy EvALuating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control", which will examine two of its major antihypertensive brands in combination with each other.

Nycomed and NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced that they have entered into a definitive agreement which licenses to Nycomed the rights to develop and commercialize GATTEX™ (teduglutide) outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders.

The Medicines Company (NASDAQ: MDCO) announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental new drug application (sNDA) for a modified dosing regimen of Angiomax® (bivalirudin) for the treatment of acute coronary syndromes (ACS), specifically in patients with unstable angina or non-segment elevation myocardial infarction (NSTEMI).

Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, and Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, today announced that Nobilon has licensed Protherics' CoVaccine HT™ adjuvant for use in pandemic influenza vaccines and seasonal influenza vaccines in elderly people.

Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus™ Therapeutics announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins™.

Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics' local, sustained release drug delivery system ReGel™.

H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. announced that Lundbeck has in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia for the majority of markets in Europe including the five major markets. Furthermore, Lundbeck holds the exclusive option to evaluate commercialization in markets outside of Europe.